Brief Amici Curiae of 82 Law, Economics, Business, and Medical Professors in Support of Respondent

U.S. Court of Appeals for the Fifth Circuit, 2019

43 Pages Posted: 16 Dec 2019

Date Written: December 16, 2019

Abstract

In FTC v. Actavis, the Supreme Court issued one of the most important antitrust rulings in the past generation, finding that settlements by which brand firms pay generics to delay entering the market could violate antitrust law. In March, the FTC applied Actavis for the first time, issuing a comprehensive ruling that offered a ringing bipartisan (5-0) condemnation of this behavior.

Impax has appealed to the Fifth Circuit, seeking to overturn this ruling. This brief, filed on behalf of 82 professors of law, economics, business, and medicine, highlights Impax's four erroneous foundations, which seek to (1) overturn Actavis; (2) downplay Impax’s concession that Endo made a reverse payment to delay entry; (3) ignore its role in delayed competition; and (4) remake antitrust law to immunize blatantly anticompetitive behavior.

The brief requests that the Fifth Circuit affirm the FTC’s opinion, which is supported by Actavis, real-world evidence, and longstanding antitrust principles.

Keywords: patent, antitrust, Actavis, pay-for-delay, reverse payment, settlement, Impax

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., Brief Amici Curiae of 82 Law, Economics, Business, and Medical Professors in Support of Respondent (December 16, 2019). U.S. Court of Appeals for the Fifth Circuit, 2019, Available at SSRN: https://ssrn.com/abstract=3504773 or http://dx.doi.org/10.2139/ssrn.3504773

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
151
Abstract Views
907
rank
214,454
PlumX Metrics